The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
Separating the winners from the value traps is a tough challenge, and that’s where StockStory comes in. Our job is to find you high-quality companies that will stand the test of time. Keeping that in mind, here is one value stock trading at a big discount to its intrinsic value and two best left ignored.
Two Value Stocks to Sell:
Quanex (NX)
Forward P/E Ratio: 9x
Starting in the seamless tube industry, Quanex (NYSE:NX) manufactures building products like window, door, kitchen, and bath cabinet components.
Why Are We Hesitant About NX?
- Day-to-day expenses have swelled relative to revenue over the last five years as its operating margin fell by 19.5 percentage points
- Earnings per share fell by 20.1% annually over the last two years while its revenue grew, partly because it diluted shareholders
- Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results
Quanex is trading at $17.83 per share, or 9x forward P/E. To fully understand why you should be careful with NX, check out our full research report (it’s free).
AerSale (ASLE)
Forward P/E Ratio: 17.7x
Providing a one-stop shop that integrates multiple services and product offerings, AerSale (NASDAQ:ASLE) delivers full-service support to mid-life commercial aircraft.
Why Do We Pass on ASLE?
- Flat sales over the last two years suggest it must find different ways to grow during this cycle
- Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 36.5 percentage points
- Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned
AerSale’s stock price of $6.02 implies a valuation ratio of 17.7x forward P/E. Read our free research report to see why you should think twice about including ASLE in your portfolio.
One Value Stock to Watch:
Halozyme Therapeutics (HALO)
Forward P/E Ratio: 8.7x
Known for transforming hours-long intravenous infusions into minutes-long subcutaneous injections, Halozyme Therapeutics (NASDAQ:HALO) develops and licenses its proprietary ENHANZE technology that enables subcutaneous delivery of injectable drugs that would otherwise require intravenous administration.
Why Do We Like HALO?
- Annual revenue growth of 32.2% over the past two years was outstanding, reflecting market share gains this cycle
- Earnings per share have massively outperformed its peers over the last five years, increasing by 28.7% annually
- Strong free cash flow margin of 46.2% enables it to reinvest or return capital consistently
At $74.72 per share, Halozyme Therapeutics trades at 8.7x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.